Adding radiotherapy to second-line therapy for advanced bile duct cancer
Part of Cancer clinical trials.
This trial tests whether adding targeted radiation (radiotherapy) to standard second-line chemotherapy helps people with advanced intrahepatic bile duct cancer that has spread to a limited number of spots (oligometastatic). It is for those whose first treatment stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic intrahepatic bile duct cancer that cannot be removed by surgery.
- Your first standard treatment has failed or stopped working.
- Cancer has spread to 5 or fewer spots in total, with no more than 3 spots in any one organ (like lung or liver).
- All cancer spots can be safely treated with radiation.
- You are 18 or older, in good daily health (ECOG 0–1), and expected to live more than 12 weeks.
- Your blood counts and liver/kidney function are within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining chemotherapy with radiation after surgery can help prevent the return of intrahepatic cholangiocarcinoma, a type of bile duct cancer. It is for people whose surgery showed a narrow margin or cancer in nearby lymph nodes.
This trial tests a new targeted drug called TT-00420 (tinengotinib) against standard chemotherapy for people with a specific type of bile duct cancer that has a change in the FGFR2 gene. The drug is designed to target and block cancer cells with that gene change, possibly slowing the cancer's growth.
This trial tests a combination of immunotherapy (adebrelimab) and chemotherapy drugs for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that hasn't been treated yet. It aims to see if adding a targeted therapy (lenvatinib) improves outcomes.
This trial tests a combination of chemotherapy directly to the liver, a targeted therapy pill, and an immunotherapy drug for people with advanced bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests whether adding targeted radiation therapy (called consolidative radiotherapy) after standard chemotherapy can help control biliary tract cancer that has spread to a few places. It is for people whose cancer has not grown during initial chemotherapy and who have a limited number of treatable spots.
This trial tests whether combining chemotherapy, radiation, and an immunotherapy drug (sintilimab) can help people with intrahepatic bile duct cancer that hasn't been treated before. It aims to see if this triple approach is safe and effective.
Hear when a new Intrahepatic Cholangiocarcinoma (Icc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.